---
title: "Cassava Sciences Appoints Dawn C. Bir to Board of Directors"
description: "Cassava Sciences Inc. has appointed Dawn C. Bir to its Board of Directors. Bir has significant experience from leadership roles at Reata Pharmaceuticals, Geron Corporation, and Soleno Therapeutics. Th"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262236431.md"
published_at: "2025-10-22T12:00:32.000Z"
---

# Cassava Sciences Appoints Dawn C. Bir to Board of Directors

> Cassava Sciences Inc. has appointed Dawn C. Bir to its Board of Directors. Bir has significant experience from leadership roles at Reata Pharmaceuticals, Geron Corporation, and Soleno Therapeutics. The company plans to initiate its first clinical study for simufilam in TSC-related epilepsy in the first half of 2026.

Cassava Sciences Inc. has appointed Dawn C. Bir to its Board of Directors. Bir brings extensive experience from leadership roles at companies including Reata Pharmaceuticals, Geron Corporation, and Soleno Therapeutics. The company is preparing to begin its first clinical study for simufilam in TSC-related epilepsy in the first half of 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cassava Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9549844-en) on October 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [SAVA.US - Cassava Sciences](https://longbridge.com/en/quote/SAVA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Cassava Sciences Faces FDA Request for More Data on Simufilam Epilepsy Trial | Cassava Sciences Inc. has submitted an IND application to the FDA for a simufilam epilepsy trial. The FDA requested more | [Link](https://longbridge.com/en/news/268413811.md) |
| FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold | Cassava Sciences confirmed that the FDA has placed a full clinical hold on its simufilam epilepsy trial, requiring addit | [Link](https://longbridge.com/en/news/270334808.md) |
| De-Risked Neurology Pipeline and Pivotal 2026 Catalysts Underpin Buy Rating on BMB-101 Franchise | TD Cowen analyst Joseph Thome has maintained a Buy rating on DRUG stock, citing strong clinical performance of BMB-101 i | [Link](https://longbridge.com/en/news/275923532.md) |
| Stoke Therapeutics spotlights durable Dravet gains, Phase 3 timeline, and new ADOA program at summit | Stoke Therapeutics (NASDAQ: STOK) presented at the Guggenheim Emerging Outlook Biotech Summit 2026, highlighting long-te | [Link](https://longbridge.com/en/news/276008727.md) |
| Praxis Precision Medicines Eyes Mid-February Dual NDA Filings, Maps ET Launch and Epilepsy Pipeline | Praxis Precision Medicines (NASDAQ: PRAX) executives discussed their regulatory plans and commercial strategies for thei | [Link](https://longbridge.com/en/news/275990084.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.